{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:20:13Z","timestamp":1794932413775,"version":"4.9.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020908","name":"Pfizer France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020908","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.129036","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:22:01Z","timestamp":1787372521000},"page":"129036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT"],"prefix":"10.1016","volume":"91","author":[{"given":"Yasmine","family":"Fahfouhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Fi\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta C.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Chillotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10340","key":"10.1016\/j.vaccine.2026.129036_bb0005","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129036_bb0010","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.05.020416","article-title":"Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis","volume":"5","author":"Shi","year":"2015","journal-title":"J Glob Health"},{"key":"10.1016\/j.vaccine.2026.129036_bb0015","doi-asserted-by":"crossref","unstructured":"Wildenbeest JG, Billard MN, Zuurbier RP, Korsten K, Langedijk AC, Ven PM van de, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med 2023 11(4):341\u201353. doi:https:\/\/doi.org\/10.1016\/S2213-2600(22)00414-3 [PubMed PMID: 36372082].","DOI":"10.1016\/S2213-2600(22)00414-3"},{"key":"10.1016\/j.vaccine.2026.129036_bb0020","doi-asserted-by":"crossref","unstructured":"Reeves RM, van Wijhe M, Tong S, Lehtonen T, Stona L, Teirlinck AC, et al. Respiratory syncytial virus-associated hospital admissions in children younger than 5 years in 7 European countries using routinely collected datasets. J Infect Dis 2020 222(Suppl 7):S599\u2013605. doi:https:\/\/doi.org\/10.1093\/infdis\/jiaa360 [PubMed PMID: 32815542].","DOI":"10.1093\/infdis\/jiaa360"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129036_bb0025","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/infdis\/jiad188","article-title":"Burden of respiratory syncytial virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years","volume":"228","author":"Del Riccio","year":"2023","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129036_bb0030","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/infdis\/jiac137","article-title":"Clinical burden of respiratory syncytial virus in hospitalized children aged \u22645 years (INSPIRE study)","volume":"226","author":"Hartmann","year":"2022","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129036_bb0035","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12879-021-06399-8","article-title":"Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018","volume":"21","author":"Demont","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129036_bb0040","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1186\/s12879-025-12039-2","article-title":"Epidemiology and economic burden of hospitalizations attributable to respiratory syncytial virus (RSV) infection among infants in France, 2016 to 2023 \u2013 EPIBREATHE study","volume":"25","author":"Cohen","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129036_bb0045","unstructured":"Justice NA, Le JK. Bronchiolitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Nov 24]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK441959\/ PubMed PMID: 28722988."},{"key":"10.1016\/j.vaccine.2026.129036_bb0050","doi-asserted-by":"crossref","unstructured":"Garegnani L, Styrmisd\u00f3ttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev 2021 11(11):CD013757. doi:https:\/\/doi.org\/10.1002\/14651858.CD013757.pub2 [PubMed PMID: 34783356; PubMed Central PMCID: PMC8594174].","DOI":"10.1002\/14651858.CD013757.pub2"},{"key":"10.1016\/j.vaccine.2026.129036_bb0055","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Haute Autorit\u00e9 de Sant\u00e9 [Internet]. [cited 2023 Feb 13]. SYNAGIS (palivizumab). Available from: https:\/\/www.has-sante.fr\/jcms\/c_2756580\/fr\/synagis-palivizumab."},{"key":"10.1016\/j.vaccine.2026.129036_bb0060","unstructured":"European medicines agency. European Medicines Agency [Text] [Internet] 2022 [cited 2023 Jul 13]. BEYFORTUS (nirsevimab). Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beyfortus."},{"key":"10.1016\/j.vaccine.2026.129036_bb0065","unstructured":"European Medicines Agency. Abrysvo - Product information [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abrysvo-epar-product-information_en.pdf."},{"issue":"16","key":"10.1016\/j.vaccine.2026.129036_bb0070","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.129036_bb0075","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Abrysvo - Comission de la Transparence [Internet]. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-20783_ABRYSVO_femmes_enceintes_PIC_INS_AvisDef_CT20783.pdf."},{"key":"10.1016\/j.vaccine.2026.129036_bb0080","unstructured":"ClinicalTrials.gov. Identifier NCT04424316, A Phase 3, Randomized, Double-blinded, Placebo-controlled Trial to Evaluate the Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy [Clinical trial registration] [Internet]. 2023 [cited 2023 Mar 6]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04424316."},{"issue":"1","key":"10.1016\/j.vaccine.2026.129036_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2024.2436183","article-title":"Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany","volume":"24","author":"Averin","year":"2025","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129036_bb0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","article-title":"Efficacy, safety, and immunogenicity of the MATISSE (maternal immunization study for safety and efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial","volume":"145","author":"Sim\u00f5es","year":"2025","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2026.129036_bb0095","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Abrysvo - avis \u00e9conomique [Internet]. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2024-09\/abrysvo_16072024_avis_economique.pdf."},{"issue":"10340","key":"10.1016\/j.vaccine.2026.129036_bb0100","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2026.129036_bb0105","unstructured":"Institut national de la statistique et des \u00e9tudes \u00e9conomiques. Taux de mortalit\u00e9 infantile - France - TABLEAU DE BORD DE L'\u00c9CONOMIE FRAN\u00c7AISE [Internet]. [cited 2025 Dec 2]. Available from: https:\/\/www.insee.fr\/fr\/outil-interactif\/5367857\/details\/20_DEM\/23_DME\/23C_Figure3."},{"key":"10.1016\/j.vaccine.2026.129036_bb0110","unstructured":"Institut National de la Statistique et des Etudes Economiques. Donn\u00e9es nationales sur les accouchements \u2212 Les naissances en 2023 et en s\u00e9ries longues | Insee [Internet]. [cited 2025 Mar 26]. Available from: https:\/\/www.insee.fr\/fr\/statistiques\/8256967?sommaire=8256973."},{"key":"10.1016\/j.vaccine.2026.129036_bb0115","unstructured":"Agence Technique de l'Information sur l'Hospitalisation. Indicateurs de sant\u00e9 p\u00e9rinatale | Stats ATIH [Internet]. [cited 2025 Mar 26]. Available from: https:\/\/www.scansante.fr\/applications\/indicateurs-de-sante-perinatale."},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2026.129036_bb0120","article-title":"Pertussis vaccination coverage in women at two months postpartum and associated factors in France, National Perinatal Survey 2021","volume":"43","author":"Dilange","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129036_bb0125","unstructured":"Sant\u00e9 Publique France. Enqu\u00eate nationale p\u00e9rinatale 2021 [Internet]. [cited 2025 Apr 24]. Available from: https:\/\/www.santepubliquefrance.fr\/etudes-et-enquetes\/enquete-nationale-perinatale-2021."},{"key":"10.1016\/j.vaccine.2026.129036_bb0130","unstructured":"BdM_IT\u00a0: fiche [Internet]. [cited 2025 Nov 26]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/\/fiche\/index_fic_medisoc.php?p_code_cip=3400930275573&p_site=AMELI."},{"key":"10.1016\/j.vaccine.2026.129036_bb0135","unstructured":"Assurance Maladie. Les honoraires et actes des pharmaciens [Internet]. [cited 2026 Jan 16]. Available from: https:\/\/www.ameli.fr\/pharmacien\/exercice-professionnel\/remunerations\/honoraires-actes-pharmaciens."},{"key":"10.1016\/j.vaccine.2026.129036_bb0140","doi-asserted-by":"crossref","unstructured":"Marc GP, Vizzotti C, Fell DB, Nunzio LD, Olszevicki S, Mankiewicz SW, et al. Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case\u2013control study. Lancet Infect Dis 2025 0(0). doi:https:\/\/doi.org\/10.1016\/S1473-3099(25)00156-2 [PubMed PMID: 40339585].","DOI":"10.1016\/S1473-3099(25)00156-2"},{"key":"10.1016\/j.vaccine.2026.129036_bb0145","doi-asserted-by":"crossref","unstructured":"Li X, Willem L, Roberfroid D, Bilcke J, Castanares Zapatero D, De Meester C, et al. Cost-effectiveness of maternal vaccine and\/or monoclonal antibody strategies against respiratory syncytial virus in Belgian infants. Npj Vaccines 2026 11(1):52. doi:https:\/\/doi.org\/10.1038\/s41541-026-01372-5.","DOI":"10.1038\/s41541-026-01372-5"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129036_bb0150","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12916-024-03687-3","article-title":"Effectiveness and efficiency of immunisation strategies to prevent RSV among infants and older adults in Germany: a modelling study","volume":"22","author":"Krauer","year":"2024","journal-title":"BMC Med"},{"issue":"21","key":"10.1016\/j.vaccine.2026.129036_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126164","article-title":"Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants","volume":"42","author":"Gebretekle","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129036_bb0160","article-title":"Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of respiratory syncytial virus disease among infants in Canada: a simulation study","volume":"28","author":"Shoukat","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.vaccine.2026.129036_bb0165","unstructured":"Sant\u00e9 Publique France. Bronchiolite\u00a0: bilan de la surveillance hivernale 2022\u20132023 | Sant\u00e9 publique France [Internet]. [cited 2025 Apr 25]. Available from: https:\/\/www.santepubliquefrance.fr\/les-actualites\/2023\/bronchiolite-bilan-de-la-surveillance-hivernale-2022-2023."},{"key":"10.1016\/j.vaccine.2026.129036_bb0170","unstructured":"Arr\u00eat\u00e9 du 31 mars 2023 fixant les modalit\u00e9s de facturation des soins dispens\u00e9s dans les conditions pr\u00e9vues au 2\u00b0 de l'article R. 162\u201333-1 du code de la s\u00e9curit\u00e9 sociale."},{"issue":"7","key":"10.1016\/j.vaccine.2026.129036_bb0175","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/INF.0000000000004360","article-title":"Assessing the burden of respiratory syncytial virus-related bronchiolitis in primary care and at 15-day and 6-month follow-up before prophylaxis in France: a test-negative study","volume":"43","author":"Rybak","year":"2024","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129036_bb0180","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s12916-020-01802-8","article-title":"Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis","volume":"18","author":"Hodgson","year":"2020","journal-title":"BMC Med"},{"issue":"16","key":"10.1016\/j.vaccine.2026.129036_bb0185","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.vaccine.2023.03.024","article-title":"Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: a multi-country prospective cohort study in Europe","volume":"41","author":"Mao","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129036_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2026.128566","article-title":"Maternal effectiveness of respiratory syncytial virus using multicenter healthcare records: a retrospective cohort study","volume":"80","author":"Kitano","year":"2026","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129036_bb0195","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13054-021-03504-w","article-title":"Surge effects and survival to hospital discharge in critical care patients with COVID-19 during the early pandemic: a cohort study","volume":"25","author":"Dale","year":"2021","journal-title":"Crit Care"},{"key":"10.1016\/j.vaccine.2026.129036_bb0200","doi-asserted-by":"crossref","unstructured":"Page B, Irving D, Amalberti R, Vincent C. Health services under pressure: a scoping review and development of a taxonomy of adaptive strategies. BMJ Qual Saf 2024 33(11):738\u201347. doi:https:\/\/doi.org\/10.1136\/bmjqs-2023-016686 [PubMed PMID: 38050158].","DOI":"10.1136\/bmjqs-2023-016686"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:50:03Z","timestamp":1794930603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26008455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":40,"alternative-id":["S0264410X26008455"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129036","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129036"}}